Sign Up Today and Learn More About Rgenta Therapeutics Stock
Invest in or calculate the value of your shares in Rgenta Therapeutics or other pre-IPO companies through EquityZen's platform.
Rgenta Therapeutics Stock (RGTH)
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.
About Rgenta Therapeutics Stock
Founded
2018
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Rgenta Therapeutics Press Mentions
Stay in the know about the latest news on Rgenta Therapeutics
5-pyrimidinecarboxamide derivatives and methods of using the same
patents • May 04, 2025
Fused triazinone derivatives and methods of using the same
patents • May 04, 2025
Rgenta Therapeutics Announces Presentation of Preclinical Data from Proprietary RSwitch Technology at the American Society of Gene And Cell Therapy (ASGCT) 2025 Annual Meeting
prnewswire • Apr 30, 2025
Fused triazinones for use in the treatment of cancer
patents • Apr 02, 2025
Small-molecule regulated alternative splicing
patents • Apr 02, 2025
Rgenta Therapeutics Management
Leadership team at Rgenta Therapeutics
Board Member
Hongbo Lu
CEO and Co-Founder
Simon Xi
Join now and verify your accreditation status to gain access to:
- Rgenta Therapeutics Current Valuation
- Rgenta Therapeutics Stock Price
- Rgenta Therapeutics Management
- Available deals in Rgenta Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Rgenta Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Rgenta Therapeutics Revenue and Financials
- Rgenta Therapeutics Highlights
- Rgenta Therapeutics Business Model
- Rgenta Therapeutics Risk Factors
- Rgenta Therapeutics Research Report from SACRA Research
Trading Rgenta Therapeutics Stock
How to invest in Rgenta Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Rgenta Therapeutics through EquityZen funds. These investments are made available by existing Rgenta Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Rgenta Therapeutics stock?
Shareholders can sell their Rgenta Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
